In such a context, a systemic mTOR inhibitor can be interesting in cancer-related treatments, but considering the key role Akt/mTORC1 signaling plays in muscle physiology and metabolism [50], this kind of drug can be detrimental for the muscles. This evidence concerns the gene AKT1 and cancer.